FIELD: medicine.
SUBSTANCE: normal saline 2 mcl containing concanavalin A 0.5 mcg - 0.5 mg is administered into a rat's vitreous cavity.
EFFECT: method enables producing an adequate model of proliferative vitreoretinopathy 8 weeks later, which is necessary to develop methods for preventing and treating the above pathology.
5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING PROLIFERATIVE RETINOPATHY IN RATS | 2014 |
|
RU2558991C1 |
| METHOD FOR SIMULATING PROLIFERATIVE VITREORETINOPATHY | 2014 |
|
RU2568368C1 |
| METHOD FOR THE TREATMENT OF PROLIFERATIVE PROCESSES OF THE POSTERIOR SEGMENT OF THE EYE | 2018 |
|
RU2684927C1 |
| METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY USING LIPOSOME-ASSOCIATED MELPHALAN IN AN EXPERIMENT | 2021 |
|
RU2772520C1 |
| METHOD FOR TREATING PROLIFERATIVE VITREORETINOPATHY | 2005 |
|
RU2284812C1 |
| SURGICAL METHOD FOR TREATING THE CASES OF REGMATOGENIC RETINAL DETACHMENT COMBINED WITH POSTERIOR DETACHMENT OF VITREOUS BODY | 2000 |
|
RU2203001C2 |
| METHOD OF MICROINVASIVE SURGICAL TREATMENT OF RECURRENCE OF RETINAL DETACHMENT IN LOWER SEGMENT WITH APPLICATION OF RETINOTOMY AND RE-TAMPONADE OF VITREOUS CAVITY | 2013 |
|
RU2548814C2 |
| METHOD FOR MODELING PROLIFERATIVE VITRORETINOPATHY | 1998 |
|
RU2161335C2 |
| METHOD FOR REMOVAL OF FIBROUS-ALTERED POSTERIOR HYALOID FACE (PHF) IN PROLIFERATIVE RETINOPATHY | 2021 |
|
RU2759234C1 |
| METHOD FOR PREVENTING PROLIFERATIVE VITREORETINOPATHY | 1999 |
|
RU2175223C2 |
